Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using our proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Our focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept we call “chemoprotection."

More >>


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

 -- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects --  – In p53...
WATERTOWN, Mass. , June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by ...
WATERTOWN, Mass. , June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a pub...

Upcoming Events

More events are coming soon.

Investor Contacts

Rick Wanstall

Chief Financial Officer and Treasurer

LifeSci Advisors, LLC.

Hans C. Vitzthum